Vivani’s emerging pipeline also includes NPM-119, which refers to the Company’s six-month, subdermal, GLP-1 (exenatide ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.

Vivani's emerging pipeline also includes NPM-119, which refers to the Company's six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a ...

Vivani Medical, Inc. (NASDAQ:VANI) and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, ...

Vivani's emerging pipeline also includes NPM-119, which refers to the Company's six-month, subdermal, GLP-1 (exenatide implant) under development for the treatment of type 2 diabetes. Development of a ...

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes ... Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing Weight Loss ...

For those with diagnosed obstructive sleep apnea, the go-to treatment is a Constant Positive ... just under the skin high on the chest. A subdermal wire extends from that unit, up through the ...

Carnegie Mellon researchers have used FRESH 3D bioprinting to create the first collagen-based microphysiologic systems, ...

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...